Efficacy and Tolerability of Insulin Degludec Versus Other Long-acting Basal Insulin Analogues in the Treatment of Type 1 and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis-Reference-Cited by-同舟云学术

Efficacy and Tolerability of Insulin Degludec Versus Other Long-acting Basal Insulin Analogues in the Treatment of Type 1 and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis

Published:2022-11 Issue:11 Volume:44 Page:1520-1533
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Dong Zhi-Yuan,Feng Ji-Hua,Zhang Jian-Feng^ORCID

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference33 articles.

1. Synthetic long-acting insulin analogs for the management of type 1 diabetes: an update;Pedersen-Bjergaard;Expert Opin Pharmacother,2021

2. Insulin glargine 300 units/mL: A new basal insulin product for diabetes mellitus;Clements;Am J Health Syst Pharm,2016

3. Introduction: Standards of Medical Care in Diabetes—2018;Diabetes Care,2018

4. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm—2017 executive summary;Garber;Endocr Pract,2017

5. A review of the pharmacological properties of insulin degludec and their clinical relevance;Haahr;Clin Pharmacokinet,2014

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perte de sensibilité aux hypoglycémies et risque d’hypoglycémie sévère : état des lieux et perspectives;Médecine des Maladies Métaboliques;2024-08

2. News in insulin treatment;Vnitřní lékařství;2024-02-26

3. Therapeutic Potential of Pectin and Its Derivatives in Chronic Diseases;Molecules;2024-02-18

4. Optimized LC-MS/MS method for quantifying insulin degludec and liraglutide in rat plasma and Tissues: Application in pharmacokinetics and biodistribution;Journal of Chromatography B;2024-02

5. Muscle‐to‐fat ratio in children and adolescents with type 1 diabetes in predicting glycaemic control and partial clinical remission;Diabetes/Metabolism Research and Reviews;2024-02